Effect of paclitaxel on proliferation and differentiation of osteoclasts in periapical periodontitis

doi:10.3969/j.issn.2095-4344.1101

Abstract

Abstract:

BACKGROUND: Paclitaxel has been shown to treat bone metastases, suggesting that it has certain effect on osteolysis diseases. However, there are few studies on paclitaxel for osteolysis diseases, and the mechanism of paclitaxel regulating osteoclast formation and function remains unclear.
OBJECTIVE: To investigate the effect of paclitaxel on the proliferation and differentiation of osteoclasts in periapical periodontitis.
METHODS: RAW264.7 cells were cultured in vitro for 24 hours and RANKL was added to identify osteoclasts by real-time PCR and tartrate-resistant acid phosphatase. Different concentrations (1, 10-1, 10-2, 10-3, 10-4, 10-5, 10-6 mol/L) of paclitaxel were used to treat osteoclasts, and the optimal concentration of osteoclasts was selected by cell counting kit-8 assay. The osteoclasts without paclitaxel were used as controls. The effect of paclitaxel on osteoclast apoptosis was detected by real-time PCR and western blot assay.
RESULTS AND CONCLUSION: The osteoclasts induced by 10-4 mol/L paclitaxel showed the weakest proliferation ability (P < 0.05), suggesting that 10-4 mol/L was the optimal concentration. After cultured by 10-4 mol/L paclitaxel for 0, 24 and 48 hours, the proliferation of osteoclasts was significantly lower than that in the control group (P < 0.05). The absorbance value of tartrate-resistant acid phosphatase of the osteoclasts cultured by 10-4 mol/L paclitaxel was significantly lower than that in the control group (P < 0.05). Real-time PCR results revealed that mRNA expression level of tartrate-resistant acid phosphatase of the osteoclasts cultured by 10-4 mol/L paclitaxel was significantly lower than that in the control group (P < 0.05). The protein expression levels of Caspase3 and PARP1 of the osteoclasts cultured by 10-4 mol/L paclitaxel were significantly higher than those in the control group. In summary, paclitaxel can inhibit the proliferation and differentiation of osteoclasts, and activate apoptosis of osteoclasts.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Periapical Periodontitis, Osteoclasts, Taxoids, Tissue Engineering

CLC Number:

R446

Wu Hui, Jiang Long, Li Xiaojie, Ji Qiushi, Xu Nuo. Effect of paclitaxel on proliferation and differentiation of osteoclasts in periapical periodontitis [J]. Chinese Journal of Tissue Engineering Research, 2019, 23(11): 1647-1651.

Figures/Tables 5

References

[1] Hosokawa Y, Hosokawa I, Ozaki K, et al. IL-27 Modulates Chemokine Production in TNF-α -Stimulated Human Oral Epithelial Cells. Cell Physiol Biochem. 2017;43(3):1198-1206.

[2] Hosokawa Y, Hosokawa I, Shindo S, et al. IL-4 Modulates CCL11 and CCL20 Productions from IL-1β-Stimulated Human Periodontal Ligament Cells. Cell Physiol Biochem. 2016;38(1): 153-159.

[3] Imai H, Fujita T, Kajiya M,et al. Mobilization of TLR4 Into Lipid Rafts by AggregatibacterActinomycetemcomitansin Gingival Epithelial Cells. Cell Physiol Biochem. 2016;39(5):1777-1786.

[4] Hans S, Mali AM. Estimation and comparison of osteopontin levels in plasma in subjects with healthy periodontium and generalized chronic periodontitis and its assessment after scaling and root planing. J Indian Soc Periodontol. 2012;16(3): 354-357.

[5] Rittling SR, Zetterberg C, Yagiz K, et al. Protective role of osteopontin in endodontic infection. Immunology. 2010;129(1): 105-114.

[6] Salinas-Muñoz M, Garrido-Flores M, Baeza M, et al. Bone resorptive activity in symptomatic and asymptomatic apical lesions of endodontic origin. Clin Oral Investig. 2017;21(8): 2613-2618.

[7] Persoon IF, Özok AR. Definitions and Epidemiology of Endodontic Infections. Current Oral Health Reports 2017; 4:278-285.

[8] Azuma MM, Samuel RO, Gomes-Filho JE, et al. The role of IL-6 on apical periodontitis: a systematic review. Int Endod J. 2014;47(7):615-621.

[9] Kalatzis-Sousa NG, Spin-Neto R, Wenzel A, et al. Use of micro-computed tomography for the assessment of periapical lesions in small rodents: a systematic review. Int Endod J. 2017;50(4):352-366..

[10] Larsen T, Fiehn N. Dental biofilm infections - an update. APMIS. 2017;125(4):376-384.

[11] Lu S, Zhang J, Zhou Z, et al. Synergistic inhibitory activity of zoledronic acid and paclitaxel on bone metastasis in nude mice. Oncol Rep. 2008;20(3):581-587.

[12] Ang ES, Pavlos NJ, Chim SM, et al. Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-κB and ERK. J Cell Biochem. 2012;113(3):946-955.

[13] Zheng X, Li Z, Chen L, et al. Self-Assembly of Porphyrin– Paclitaxel Conjugates Into Nanomedicines:Enhanced Cytotoxicity due to Endosomal Escape. Chem Asian J. 2016; 11(12):1780-1784

[14] Kundranda M, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther. 2015;9:3767-3777.

[15] Drobecq H, Boll E, Sénéchal M,et al. A Central Cysteine Residue Is Essential for the Thermal Stability and Function of SUMO-1 Protein and SUMO-1 Peptide–Protein Conjugates. Bioconjug Chem. 2016;27(6):1540-1546.

[16] Huang Y, Liang W, Yang Y, et al. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma. BMC Cancer. 2016;16:464.

[17] Hurria A, Blanchard MS, Synold TW, et al. Age-Related Changes in Nanoparticle Albumin-Bound Paclitaxel Pharmacokinetics and Pharmacodynamics: Influence of Chronological Versus Functional Age. The Oncologist 2015; 20:37-44.

[18] Kendra KL, Plummer R, Salgia R, et al. A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. Mol Cancer Ther. 2015;14(2):461-469.

[19] Oudin MJ, Barbier L, Schäfer C,et al. MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. Mol Cancer Ther. 2017;16(1):143-155.

[20] Rezazadeh M, Emami J, Hasanzadeh F, et al. In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle. Drug Deliv. 2016;23(5):1707-1717.

[21] Rugo HS, Barry WT, Moreno-Aspitia A,et al. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015;33(21):2361-2369.

[22] Tamura K, Inoue K, Masuda N, et al. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Sci. 2017;108(5):987-994.

[23] Villaruz LC, Socinski MA. Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. Eur J Cancer. 2016;56:162-171.

[24] Yang M, Yu T, Wang Y, et al. Vaginal Delivery of Paclitaxel via Nanoparticles with Non-Mucoadhesive Surfaces Suppresses Cervical Tumor Growth. Adv Healthc Mater. 2014;3(7): 1044-1052.

[25] Sanchez-Torres A, Sanchez-Garces M, Gay-Escoda C. Materials and prognostic factors of bone regeneration in periapical surgery: A systematic review. Med Oral Patol Oral Cir Bucal. 2014;19(4):e419-25.

[26] Qu C, Meng H, Han J. Implant periapical lesion - a review and a case report with histological evaluation. Clin Oral Implants Res. 2014;25(9):1099-1104.

[27] Petersson A, Axelsson S, Davidson T,et al. Radiological diagnosis of periapical bone tissue lesions in endodontics: a systematic review. Int Endod J. 2012;45(9):783-801.

[28] Zoellner H. Dental Infection and Vascular Disease. Semin Thromb Hemost. 2011;37(3):181-192.

[29] Maeda H, Wada N, Nakamuta H, et al. Human periapical granulation tissue contains osteogenic cells. Cell Tissue Res. 2004;315(2):203-208.

[30] Yilmaz E, Watkins SC, Gold MS. Paclitaxel-induced increase in mitochondrial volume mediates dysregulation of intracellular Ca2+ in putative nociceptive glabrous skin neurons from the rat. Cell Calcium. 2017;62:16-28.

[31] Yuan Y, Zhang Y, Shi L, et al. Clinical Research on Albumin-Bound Paclitaxel-Based Chemotherapy for Advanced Esophageal Cancer. Asian Pac J Cancer Prev. 2015;16(12):4993-4996.

[32] Zhang H, Li Y, de Carvalho-Barbosa M, et al. Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. J Pain. 2016; 17(7):775-786.